Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Age up to 75 Years Does Not Influence the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Dipenkumar Modi, MD, Abhinav Deol, MD, Seongho Kim, PhD, Kendra Mellert, M.S.A.; C.C.R.P., Marie Ventimiglia, Alavi Asif, MD, Divaya Bhutani, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2016) 128 (22): 3501.

https://doi.org/10.1182/blood.V128.22.3501.3501

Published: 2016

Journal Articles

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

J. Christine Ye, MD MSc, Lakshminarayanan Nandagopal, MD, Marie Ventimiglia, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Jeffrey Zonder, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 2518.

https://doi.org/10.1182/blood.V124.21.2518.2518

Published: 2014

Journal Articles

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Lakshminarayanan Nandagopal, MD, J. Christine Ye, MD MSc, Marie Ventimiglia, Muneer H. Abidi, MD, Lois Ayash, MD, Jeffrey Zonder, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 5904.

https://doi.org/10.1182/blood.V124.21.5904.5904

Published: 2014

Journal Articles

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Voravit Ratanatharathorn, MD, Abhinav Deol, MD, Lois Ayash, MD, Divaya Bhutani, MD, Lawrence G Lum, MD, DSc, Zaid Al-Kadhimi, MD, Muneer H. Abidi, MD, Marie Ventimiglia, Kendra Mellert, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 3300.

https://doi.org/10.1182/blood.V122.21.3300.3300

Published: 2013

Journal Articles

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/ 2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

Muneer H. Abidi, MD, Nishant Tageja, MD, Lawrence G. Lum, MD, DSC, Judith Abrams, Zaid Al-Kadhimi, Lois Ayash, Simon Cronin, Pharm, D, Marie Ventimiglia, Abhinav Deol, MBBS, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2010) 116 (21): 2401.

https://doi.org/10.1182/blood.V116.21.2401.2401

Published: 2010

Journal Articles

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Muneer H. Abidi, MD, Zartash Gul, MD, Lawrence G. Lum, MD, DSC, Judith Abrams, Simon Cronin, Pharm, D, Marie Ventimiglia, Abhinav Deol, MBBS, MD, Lois Ayash, Zaid Al-Kadhimi, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2010) 116 (21): 2387.

https://doi.org/10.1182/blood.V116.21.2387.2387

Published: 2010

NARROW

Age up to 75 Years Does Not Influence the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/ 2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Age up to 75 Years Does Not Influence the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/ 2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only